Ultragenyx Pharmaceutical | RARE - Equity Capital And Reserves


Ultragenyx Pharmaceutical reported $9.16M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Immunic USD 10.5M 23.41M Sep/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Kyowa Hakko Kirin JPY 893.33B 47.21B Dec/2025
MacroGenics USD 67M 20.38M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025
Xoma USD 87.94M 15.5M Sep/2025